Short answer
Disc Medicine, Inc. (IRON) filed its Q2 2026 10-Q quarterly report on Jul 30, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$60M
- −7.8% YoY · +6.3% QoQ
- EPS (diluted)
- −$1.54
- +3.1% YoY · +6.7% QoQ
Source: XBRL data from the Disc Medicine, Inc. (IRON) Q2 2026 10-Q on SEC EDGAR. USD.
Disc Medicine, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged year over year; no product sales since inception
- Operating margin not applicable; net loss $59.5M vs $55.2M YoY
- Best R&D performer: selcodebart spending $12.4M, up $7.7M YoY
- Worst R&D performer: bitopertin spending $8.7M, down $15.0M YoY
- Cash, equivalents and securities $717.7M; operating cash use $106.4M and debt proceeds $30.0M through June 30
Risk Factors
- Net losses $123.0 million for six months ended June 30, 2026, versus $89.3 million in 2025
- Cash, equivalents, and marketable securities expected to fund operations and debt service into 2029
- Hercules term loan up to $200.0 million, maturing December 1, 2029, secured by substantially all non-intellectual-property assets
- Clinical programs remain exposed to FDA demands for additional trials or stricter approval conditions
- Three product candidates in clinical development, with none having completed Phase 3 trials
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Disc Medicine, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.